Breast surgery type was significantly associated with periods, tumor subtypes, cT stages, and cN stages: 36.8% (103/280) of breast conservative surgery during P1, 43.7% (220/503) during P2 and 48.5% (410/846) during P3; 38.4% (151/393) of breast conservative surgery for Luminal-A tumors, 45.4% (90/198) for Luminal-B HER2−, 42.7% (129/302) for Luminal-B HER2+, 34.5% (76/220) for HER2+, and 55.5% (285/513) for triple-negative; 52.9% (127/240) for cT0-1 tumors, 54.4% (509/935) for cT2, and 24.3% (85/350) for cT3 (Table 8). This evidence concerns the gene ERBB2 and neoplasm.